PLUS: 125 new Studies from 11/1 to Monday 11/11 Start at the Bottom:
Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis
Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments
125 STUDIES FROM 11/1 to Monday 11/11 are below:
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers
A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis.
Teriflunomide in relapsing multiple sclerosis: therapeutic utility.
Magnetic resonance monitoring of lesion evolution in multiple sclerosis.
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.
Epidemiology in multiple sclerosis: a pilgrim's progress.
[Multiple sclerosis and pregnancy].
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study.
Multicentre absolute myelin water content mapping: Development of a whole brain atlas and application to low-grade multiple sclerosis.
Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis.
Mimotopic peptide immunotherapy for the treatment of multiple sclerosis, an inflammatory autoimmune disease.
P300 wave changes in patients with multiple sclerosis.
Is There Extra Cost of Institutional Care for MS Patients?
Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis.
Multiple cancers in a patient with systemic sclerosis and aggravated interstitial lung disease by chemotherapy.
Growth hormone response to clonidine administration for evaluation of autonomic dysfunction in multiple sclerosis patients.
Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study.
Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis.
Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.
A Randomized, Double-Blind, Placebo-Controlled Trial of Duloxetine for the Treatment of Pain in Patients withMultiple Sclerosis.
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study.
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
Stress in multiple sclerosis: review of new developments and future directions.
Does pain in individuals with multiple sclerosis affect employment? A systematic review and meta-analysis.
Emerging injectable therapies for multiple sclerosis.
Aerobic exercise increases hippocampal volume and improves memory in multiple sclerosis: Preliminary findings.
Effect of textured insoles on balance and gait in people with multiple sclerosis: an exploratory trial.
Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity.
Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study.
Immunomodulatory and therapeutic effects of Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.
Measuring response in the gastrointestinal tract in systemic sclerosis.
Natalizumab (tysabri)-associated progressive multifocal leukoencephalopathy: insights from perfusion magnetic resonance imaging.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Neuropsychological rehabilitation has beneficial effects on perceived cognitive deficits in multiple sclerosisduring nine-month follow-up.
The discovery of natalizumab, a potent therapeutic for multiple sclerosis
Ginkgo biloba does not improve cognitive function in MS
Combination of Robot-Assisted and Conventional Body-Weight-Supported Treadmill Training Improves Gait in Persons With Multiple Sclerosis: A Pilot Study.
Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling.
OASIS is Automated Statistical Inference for Segmentation, with applications to multiple sclerosis lesion segmentation in MRI.
Interventions for children coping with parental multiple sclerosis: A systematic review.
A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Speed of word retrieval in multiple sclerosis.
Gray matter damage predicts the accumulation of disability 13 years later in MS.
Use of services for multiple sclerosis patients according to edss.
Using routine point-of-care data for research: the East london multiple sclerosis cohort.
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial.
Immunoregulatory Effects of Interferon-β in Suppression of Th17 cells.Combination of Robot-Assisted and Conventional Body-Weight-Supported Treadmill Training Improves Gait in Persons With Multiple Sclerosis: A Pilot Study.
Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling.
OASIS is Automated Statistical Inference for Segmentation, with applications to multiple sclerosis lesion segmentation in MRI.
Interventions for children coping with parental multiple sclerosis: A systematic review.
A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Speed of word retrieval in multiple sclerosis.
Gray matter damage predicts the accumulation of disability 13 years later in MS.
Use of services for multiple sclerosis patients according to edss.
Using routine point-of-care data for research: the East london multiple sclerosis cohort.
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial.
Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling.
Intra-individual variability in information processing speed reflects white matter microstructure in multiple sclerosis.
Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study.
OASIS is Automated Statistical Inference for Segmentation, with applications to multiple sclerosis lesion segmentation in MRI.
DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis.
A comprehensive approach to the segmentation of multichannel three-dimensional MR brain images in multiple sclerosis.
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study.
Multicentre absolute myelin water content mapping: Development of a whole brain atlas and application to low-grade multiple sclerosis.
Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis.
Mimotopic peptide immunotherapy for the treatment of multiple sclerosis, an inflammatory autoimmune disease.
The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases.
Relative contribution of cognitive and physical disability components to quality of life in MS.
Improvement of driving skills in persons with Relapsing-Remitting Multiple Sclerosis: a pilot study.
Initial Immunopathogenesis of Multiple Sclerosis: Innate Immune Response.
TNFRSF1A in multiple sclerosis: A tale of soluble receptors and signaling cascades.
Clinically meaningful performance benchmarks in MS: Timed 25-Foot Walk and the real world.
A nine-year population-based cohort study on the risk of multiple sclerosis in patients with optic neuritis.
Mood and coping in clinically isolated syndrome and multiple sclerosis.
A single session of 1 mA anodal tDCS-supported motor training does not improve motor performance in patients with multiple sclerosis.
Regional brain atrophy and functional connectivity changes related to fatigue in multiple sclerosis.
Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: An MEG source-space study.
Fatty fish intake is associated with decreased occurrence of multiple sclerosis.
Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis.
A Randomized, Double-Blind, Placebo-Controlled Trial of Duloxetine for the Treatment of Pain in Patients with Multiple Sclerosis.
Rare Inflammatory Diseases of the White Matter and Mimics of Multiple Sclerosis and Related Disorders.
Retinal Nerve Fiber Layer Thickness, Brain Atrophy, and Disability in Multiple Sclerosis Patients.
THE BRADYKINESIA-AKINESIA INCOORDINATION TEST: A SIMPLE OBJECTIVE TEST IN MULTIPLE SCLEROSIS.
The CYP27B1 variant associated with increased risk of autoimmune disease is underexpressed in tolerising dendritic cells.
Intraoperative smile in a multiple sclerosis patient with medication-refractory tremor.
